

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER: **10/561,618**
FILING DATE: **05/05/2006**
FIRST NAMED INVENTOR: **Brenda F. Baker**
ART UNIT: **1635**
EXAMINER NAME: **Tracy Ann Vivlemore**
ATTORNEY DOCKET NUMBER: **CORE0005USA**
TITLE: **OLIGOMERIC COMPOUNDS FOR USE
IN GENE MODULATION**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Form PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

☒ within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;

☐ before the mailing of a first official action after filing of a request for continued examination (RCE) under 37 C.F.R. § 1.114;

☐ after three months of the filing date of this national application or the date of entry of the national stage in an international application, or after the mailing date of the first official action on the merits, whichever event last occurred, but before that mailing date of the first office action to occur of either: (1) a final action under 37 C.F.R. § 1.113; or (2) an action that otherwise closes prosecution in the application, and:

☐ attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c); OR

☐ Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:

☐ each item of the information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement;

OR

☐ no item of information contained in this Information Disclosure Statement was cited in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Statement.

☐ on or before the payment of the issue fee but after the mailing date of the first to occur of either: (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application, and:

☐ Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:

☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign

patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

OR

☐ no item of information contained in this Information Disclosure Statement was cited in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Statement. AND

☐ attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c); OR

☐ after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 C.F.R. § 1.97(i), although the information may not be considered by the USPTO.

☒ Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. , filed on , and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 C.F.R. § 1.98(d).


☒ This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 C.F.R. § 1.98(a)(2)(i), copies of each U.S. Patent and each U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed.

☐ Each item of information contained in this Information Disclosure Statement was cited in the communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. § 1.56(c)

more than thirty days prior to the filing of this Information Disclosure Statement 37
C.F.R. § 1.704(d).

☒ Applicant submits that no fee is required for the consideration of this Information
Disclosure Statement. However, if a fee is due, the Commissioner is hereby authorized
to charge Deposit Account No 500252 referencing case number CORE0005USA.
Consideration of the listed references and favorable action are solicited.

Respectfully submitted,



Dated: 8-8-06

Robert S. Andrews
Registration No.: **44,508**
Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	CORE0005USA

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US-5,484,908	01-16-1996	Froehler et al.	
	AB	US-5,898,031	04-29-1999	Crooke	
	AC	US-6,005,087	12-21-1999	Cook et al.	
	AD	US-6,107,094	08-22-2000	Crooke	
	AE	US-2004/0259247	12-23-2004	Tuschl et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AF	WO 99/32619 A1	07-01-1999	Carnegie Institute		
	AG	WO 00/44895 A1	08-03-2000	Kreutzer et al.		
	AH	WO 00/44914 A1	08-03-2000	Medical College		
	AI	WO 00/49035 A1	08-24-2000	General Hospital		
	AJ	WO 00/63364 A2	10-26-2000	American Home		
	AK	WO 01/29058 A1	04-26-2001	University of Massachusetts		
	AL	WO 01/36641 A2	05-25-2001	Chiron Corp.		
	AM	WO 01/36646 A1	05-25-2001	Cancer Res.		
	AN	WO 01/48183 A2	07-05-2001	Devgen NV		
	AO	WO 01/75164 A2	10-11-2001	Whitehead Inst.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	CORE0005USA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AP	BASS, B. L., "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> (2000) 101(3):235-238.	
	AQ	BOUTLA A. et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ," <i>Current Biology</i> (2001) 11(22):1776-1780.	
	AR	BRAASCH, D. A. et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> (2003) 42(26):7967-7975.	
	AS	BRANTL, S., "Antisense-RNA regulation and RNA interference," <i>Biochimica et Biophysica Acta</i> (2002) 1575(1-3):15-25.	
	AT	BUHR, C. A. et al., "Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2'-deoxyguanosine and 7-deaza-2'-deoxyadenosine," <i>Nucleic Acids Research</i> (1996) 24(15):2974-2980.	
	AU	CHIU, Y.-L. et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> (2003) 9(9):1034-1048.	
	AV	COGONI, C. et al., "Post-transcriptional gene silencing across kingdoms," <i>Curr Opin Genet Dev.</i> (2000) 10(6):638-643.	
	AW	ELBASHIR, S. M. et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes Dev.</i> (2001) 15(2):188-200.	
	AX	ELBASHIR, S. M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> (2001) 411(6836):494-498.	
	AY	ELBASHIR, S. M. et al., "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>EMBO</i> (2001) 20(23):6877-6887.	
	AZ	FIRE, A. et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," <i>Nature</i> (1998) 391:806-811.	
	BA	GALLO, M. et al., "2'-C-Methyluridine phosphoramidite: a new building block for the preparation of RNA analogues carrying the 2'-hydroxyl group," <i>Tetrahedron</i> (2001) 57(27):5707-5713.	
	BB	GUILLERM, D. et al., "Synthesis of 4'-fluoroadenosine as an inhibitor of S-adenosyl-L-homocysteine hydrolase," <i>Bioorganic & Medicinal Chemistry Letters</i> (1995) 5(14):1455-1460.	
	BC	GUO, S. et al., " <i>par-1</i> , a Gene Required for Establishing Polarity in <i>C. elegans</i> Embryos, Encodes a Putative Ser/Thr Kinase That Is Asymmetrically Distributed," <i>Cell</i> (1995) 81(4):611-620.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	CORE0005USA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BD	GURU, T., "A silence that speaks volumes," <i>Nature</i> (2000) 404:804-808.	
	BE	GUTIERREZ, A. J. et al., "Antisense Gene Inhibition by C-5-Substituted Deoxyuridine-Containing Oligodeoxynucleotides," <i>Biochemistry</i> (1997) 36(4):743-748.	
	BF	HARRY O'KURU, R. E. et al., "A Short, Flexible Route toward 2'-C-Branched Ribonucleosides," <i>J. Org. Chem.</i> (1997) 62(6):1754-1759.	
	BG	JACOBSON, K. A. et al., "Methanocarba Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists," <i>J. Med. Chem.</i> (2000) 43(11):2196-2203.	
	BH	JORGENSEN, R. A. et al., "Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DNA sequences," <i>Plant Mol. Biol.</i> (1996) 31(5):957-973.	
	BI	KAWASAKI, A. M. et al., "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> (1993) 36(7):831-841.	
	BJ	KHVOROVA, A. et al., "Functional siRNAs and miRNAs Exhibit Strand Bias," <i>Cell</i> (2003) 115(2):209-216.	
	BK	KURRECK, J., "Antisense technologies, Improvement through novel chemical modifications," <i>Eur. J. Biochem.</i> (2003) 270(8):1628-1644.	
	BL	LEE, K. et al., "Ring-Constrained (N)-Methanocarba Nucleosides as Adenosine Receptor Agonists: Independent 5'-Uronamide and 2'-Deoxy Modifications," <i>Bioorganic & Medicinal Chemistry Letters</i> (2001) 11(10):1333-1337.	
	BM	LIN, K.-Y. et al., "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acids," <i>J. Am. Chem. Soc.</i> (1998) 120(33):8531-8532.	
	BN	MARTINEZ, J. et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> (2002) 110(5):563-574.	
	BO	MELLITZER, G. et al., "Spatial and temporal 'knock down' of gene expression by electroporation of double-stranded RNA and morpholinos into early postimplantation mouse embryos," <i>Mechanisms of Development</i> (2002) 118(1-2):57-63.	
	BP	MONTGOMERY, M. K. et al., "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> (1998) 95(26):15502-15507.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	CORE0005USA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BQ	MORITA, K. et al., "2'-O,4'-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug," <i>Bioorganic & Medicinal Chemistry Letters</i> (2002) 12(1):73-76.	
	BR	MOULDS, C. et al., "Site and Mechanism of Antisense Inhibition by C-5 Propyne Oligonucleotides," <i>Biochemistry</i> (1995) 34(15):5044-5053.	
	BS	NAPOLI, C. et al., "Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans," <i>Plant Cell</i> (1990) 2(4):279-289.	
	BT	NISHIKURA, K. et al., "A Short Primer on RNAi: RNA-Directed RNA Polymerase Acts as a Key Catalyst," <i>Cell</i> (2001) 107(4):415-418.	
	BU	OWEN, G. R. et al., "4'-Substituted Nucleosides. 3. Synthesis of Some 4'-Fluorouridine Derivatives," <i>J. Org. Chem.</i> (1976) 41(18):3010-3017.	
	BV	PARRISH, S. et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> (2000) 6(5):1077-1087.	
	BW	SCHWARZ, D. S. et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> (2002) 10(3):537-548.	
	BX	SCHWARZ, D. S. et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> (2003) 115(2):199-208.	
	BY	SOUTSCHEK, J. et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> (2004) 432(7014):173-178.	
	BZ	SINGH, S. K. et al., "LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition," <i>Chem Commun</i> (1998) (4):455-456.	
	CA	TABARA, H. et al., "RNAi in <i>C. elegans</i> : Soaking in the Genome Sequence," <i>Science</i> (1998) 282(5388):430-431.	
	CB	TANG, X.-Q. et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-β-Methylcytidine and Their Incorporation into Oligonucleotides," <i>J. Org. Chem.</i> (1999) 64(3):747-754.	
	CC	TIJSTERMAN, M. et al., "RNA Helicase MUT-14-Dependent Gene Silencing Triggered in <i>C. elegans</i> by Short Antisense RNAs," <i>Science</i> (2002) 295(5555):694-697.	
	CD	TIMMONS, L. et al., "Specific interference by ingested dsRNA," <i>Nature</i> (1998) 395(6705):854.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	5	of	5
-------	---	----	---

<i>Application Number</i>	10/561,618
<i>Filing Date</i>	05/05/2006
<i>First Named Inventor</i>	Brenda F. Baker
<i>Art Unit</i>	1635
<i>Examiner Name</i>	Tracy Ann Vivlmore
<i>Attorney Docket Number</i>	CORE0005USA

[illegible]Date
Considered

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.